HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Hisashi Tsurumi Selected Research

VAP-cyclo protocol

6/2017CHOP or THP-COP regimens in the treatment of newly diagnosed peripheral T-cell lymphoma, not otherwise specified: a comparison of doxorubicin and pirarubicin.
1/2014Serum soluble tumor necrosis factor receptor 1 level is associated with the outcome of diffuse large B-cell lymphoma patients treated with the CHOP or R-CHOP regimen.
10/2013Serum level of soluble tumor necrosis factor receptor 2 is associated with the outcome of patients with diffuse large B-cell lymphoma treated with the R-CHOP regimen.
5/2012Serum soluble interleukin-2 receptor (sIL-2R) level is associated with the outcome of patients with diffuse large B cell lymphoma treated with R-CHOP regimens.
2/2004Biweekly CHOP or THP-COP regimens in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma. A comparison of doxorubicin and pirarubicin: a randomized phase II study.
11/2002[Nasal NK cell lymphoma with hemophagocytic syndrome developed tumor lysis syndrome after CHOP therapy].

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Hisashi Tsurumi Research Topics

Disease

34Neoplasms (Cancer)
01/2021 - 11/2002
22Carcinogenesis
10/2017 - 01/2005
20Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse)
11/2021 - 06/2005
15Hepatocellular Carcinoma (Hepatoma)
01/2016 - 05/2004
12Lymphoma (Lymphomas)
06/2019 - 11/2002
11Inflammation (Inflammations)
10/2017 - 01/2005
11Non-Hodgkin Lymphoma (Lymphosarcoma)
01/2017 - 06/2002
11Obesity
01/2015 - 09/2008
10Body Weight (Weight, Body)
10/2018 - 01/2005
8Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
10/2020 - 08/2007
6Leukemia
02/2022 - 05/2004
6Insulin Resistance
01/2015 - 05/2009
5Febrile Neutropenia
02/2022 - 06/2008
5Hematologic Neoplasms (Hematological Malignancy)
01/2017 - 05/2004
5Multiple Myeloma
01/2016 - 01/2008
5Aberrant Crypt Foci
07/2014 - 09/2008
5Liver Cirrhosis (Hepatic Cirrhosis)
02/2013 - 12/2009
5Colonic Neoplasms (Colon Cancer)
05/2012 - 11/2007
4Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular)
02/2022 - 09/2005
4BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
10/2018 - 06/2011
4Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral)
12/2017 - 01/2009
4Colorectal Neoplasms (Colorectal Cancer)
09/2012 - 11/2007
3Neutropenia
02/2022 - 12/2005
3Philadelphia Chromosome
02/2022 - 06/2011
3Stomatitis
01/2021 - 12/2014
3Myelodysplastic Syndromes (Myelodysplastic Syndrome)
10/2020 - 08/2003
3B-Cell Lymphoma (Lymphoma, B Cell)
04/2020 - 02/2012
3Pneumonia (Pneumonitis)
01/2020 - 01/2005
3Cardiotoxicity
10/2018 - 02/2004
3T-Cell Lymphoma (Lymphoma, T Cell)
12/2017 - 01/2008
3Pain (Aches)
08/2016 - 01/2008
3Malnutrition (Nutritional Deficiencies)
04/2014 - 12/2012
3Fibrosis (Cirrhosis)
01/2013 - 12/2009
3Anemia
01/2011 - 05/2005
3Fever (Fevers)
11/2010 - 11/2003
2Thrombocytopenia (Thrombopenia)
02/2022 - 01/2019
2Mantle-Cell Lymphoma (Lymphoma, Mantle Cell)
02/2022 - 09/2014
2Mycoses (Diseases, Fungus)
01/2020 - 11/2010
2Renal Insufficiency (Renal Failure)
01/2019 - 01/2015
2Pure Red-Cell Aplasia
11/2018 - 08/2007
2Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
11/2018 - 01/2008

Drug/Important Bio-Agent (IBA)

18Prednisolone (Predate)FDA LinkGeneric
01/2020 - 06/2002
18Cyclophosphamide (Cytoxan)FDA LinkGeneric
01/2020 - 06/2002
17Rituximab (Mabthera)FDA Link
02/2022 - 10/2006
16Vincristine (Oncovin)FDA LinkGeneric
10/2018 - 06/2002
14Proteins (Proteins, Gene)FDA Link
10/2020 - 05/2004
13Doxorubicin (Adriamycin)FDA LinkGeneric
10/2018 - 02/2004
9Indoleamine-Pyrrole 2,3,-Dioxygenase (Indoleamine 2,3 Dioxygenase)IBA
04/2020 - 04/2011
8pirarubicinIBA
10/2018 - 02/2004
8KynurenineIBA
12/2017 - 04/2010
83,7,11,15- tetramethyl- 2,4,6,10,14- hexadecapentaenoic acidIBA
10/2013 - 05/2004
6Diethylnitrosamine (N-Nitrosodiethylamine)IBA
01/2016 - 02/2010
6Messenger RNA (mRNA)IBA
01/2016 - 01/2011
6AdipokinesIBA
01/2015 - 07/2010
5AzoxymethaneIBA
07/2014 - 05/2008
5Retinoid X Receptors (Retinoid X Receptor)IBA
10/2012 - 03/2007
5epigallocatechin gallate (epigallocatechin-3-gallate)IBA
09/2012 - 05/2008
5RetinoidsIBA
11/2009 - 05/2004
4Granulocyte Colony-Stimulating Factor (G-CSF)IBA
02/2022 - 12/2005
4Tryptophan (L-Tryptophan)FDA Link
04/2020 - 09/2012
4Etoposide (VP 16)FDA LinkGeneric
09/2017 - 06/2002
4TeaIBA
01/2013 - 05/2008
4Branched-Chain Amino AcidsIBA
12/2012 - 05/2009
4Interleukin-2 Receptors (IL 2 Receptor)IBA
05/2012 - 11/2002
4beta CateninIBA
07/2010 - 10/2007
4Insulin-Like PeptidesIBA
05/2010 - 09/2008
3Cytarabine (Cytosar-U)FDA LinkGeneric
02/2022 - 08/2007
3MethylprednisoloneFDA LinkGeneric
02/2022 - 08/2003
3polaprezinc (Z 103)IBA
01/2021 - 12/2014
3Monoclonal AntibodiesIBA
04/2020 - 06/2005
3Interleukin-6 (Interleukin 6)IBA
11/2018 - 01/2011
3Carboplatin (JM8)FDA LinkGeneric
09/2017 - 06/2002
3Red Fluorescent ProteinIBA
04/2016 - 09/2015
3EnzymesIBA
01/2016 - 09/2012
3Antineoplastic Agents (Antineoplastics)IBA
01/2015 - 05/2004
3LigandsIBA
10/2012 - 05/2004
3Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA
10/2012 - 05/2004
3Pharmaceutical PreparationsIBA
06/2012 - 01/2009
3Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
06/2011 - 07/2002
3Drinking WaterIBA
06/2011 - 05/2008
3tyrosine receptor (receptor, tyrosine)IBA
05/2010 - 10/2009
3Phosphotransferases (Kinase)IBA
05/2010 - 10/2009
3Retinoid X Receptor alphaIBA
11/2009 - 10/2007
3Vitamin A (Retinol)FDA LinkGeneric
01/2009 - 05/2004
3AlitretinoinFDA Link
01/2009 - 11/2007
2Dasatinib (BMS 354825)FDA Link
02/2022 - 10/2018
2Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
01/2021 - 05/2010
2ProgranulinsIBA
01/2021 - 10/2017
2IfosfamideFDA LinkGeneric
09/2017 - 06/2002

Therapy/Procedure

21Drug Therapy (Chemotherapy)
01/2021 - 06/2002
20Therapeutics
02/2022 - 06/2002
14Chemoprevention
01/2015 - 05/2004
6VAP-cyclo protocol
06/2017 - 11/2002
5Intraperitoneal Injections
01/2016 - 05/2008
4Hematopoietic Stem Cell Transplantation
01/2021 - 12/2014
3Radiotherapy
08/2016 - 01/2005
3Aftercare (After-Treatment)
03/2013 - 01/2009
2Transplantation
01/2021 - 09/2015
2Induction Chemotherapy
02/2019 - 06/2011
2Stem Cell Transplantation
11/2018 - 10/2014